Epidemiology of Vascular Inflammation & Atherosclerosis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00087893 |
Recruitment Status
:
Completed
First Posted
: July 19, 2004
Last Update Posted
: September 27, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Atherosclerosis Cardiovascular Diseases Heart Diseases Coronary Arteriosclerosis Coronary Disease Cerebral Arteriosclerosis Cerebrovascular Accident |
BACKGROUND:
Currently, the predominant hypothesis regarding atherosclerosis is that it is in major part driven by two independent pathways: hyperlipidemia (the "stimulation") and inflammation (the "response"). Although vascular cells mediate the influence of inflammation on atherosclerosis, very little is known about vascular cell epidemiology and the relationship of vascular cell phenotypes to atherosclerosis. The main hypothesis tested in this study is that variation in vascular cell biology is related to the population variation in atherosclerosis.
DESIGN NARRATIVE:
The cross-sectional study will be nested within a large cohort study, the Multiethnic Study of Atherosclerosis (MESA). A partial sample of 1,000 individuals who have undergone other special laboratory analyses will be identified and new measures collected as part of their upcoming site visit. A number of novel cellular phenotypes describing the innate immune response (monocyte activation, natural killer and T cell counts), the adaptive immune response (TH1 and TH2 helper cells, and memory T cells), and vessel integrity (circulating endothelial progenitor cells) will be measured in these participants. Plasma constituents will also be measured that relate to the cellular phenotypes. The overall goal is to test the hypothesis that these novel phenotypes are associated with subclinical atherosclerosis in the coronary and carotid arteries assessed by quantification of coronary calcification (CAC) and B-mode ultrasound (CIMT), in addition to the other subclinical measures available from the MESA cohort.
Study Type : | Observational |
Actual Enrollment : | 931 participants |
Observational Model: | Cohort |
Time Perspective: | Cross-Sectional |
Study Start Date : | July 2004 |
Actual Primary Completion Date : | June 2008 |
Actual Study Completion Date : | June 2008 |

- T helper bias [ Time Frame: 2008 ]T helper bias is a stable phenotype in people, with few environmental drives; the main environmental driver appears to be anti-CMV titer; this has led to our view that genetics probably plays a role, and our current GWAS efforts using our unique MESA-Inflammation cellular phenotypes.
- T helper bias toward Th1 cells [ Time Frame: 2008 ]T helper bias towards Th1 cells is strongly associated with measures of atherosclerosis in the population-based study MESA-Inflammation (both coronary calcification and carotid wall thickness) after fully adjusting for traditional and novel CVD risk factors. This is consistent with our original hypothesis, based on small human studies and mouse data.
- atherosclerosis [ Time Frame: 2008 ]Both IL-10 and sIL-2R are also associated with atherosclerosis in humans as we hypothesized.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 45 Years to 84 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00087893
Principal Investigator: | Russell Tracy | University of Vermont |
Responsible Party: | Russell Tracy, Professor of Pathology, University of Vermont |
ClinicalTrials.gov Identifier: | NCT00087893 History of Changes |
Other Study ID Numbers: |
1261 R01HL077449 ( U.S. NIH Grant/Contract ) |
First Posted: | July 19, 2004 Key Record Dates |
Last Update Posted: | September 27, 2013 |
Last Verified: | September 2013 |
Additional relevant MeSH terms:
Cardiovascular Diseases Heart Diseases Atherosclerosis Coronary Disease Coronary Artery Disease Stroke Arteriosclerosis Myocardial Ischemia |
Intracranial Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Intracranial Arterial Diseases |